tecovirimat: A potent and specific inhibitor of orthopoxvirus replication. It is used for the treatment of SMALLPOX and other orthopoxvirus infections, including MONKEYPOX under expanded access investigational new drug protocol (https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html). [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 16124688 |
| CHEMBL ID | 1257073 |
| SCHEMBL ID | 404743 |
| SCHEMBL ID | 21670085 |
| MeSH ID | M0491233 |
| Synonym |
|---|
| tecovirimat |
| siga-246 |
| st-246 |
| 869572-92-9 |
| f925rr824r , |
| tecovirimat [usan:inn] |
| tpoxx |
| n-((3ar,4r,4ar,5as,6s,6as)-1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa(f)isoindol-2(1h)-yl)-4-(trifluoromethyl)benzamide |
| siga 246 |
| unii-f925rr824r |
| st 246 |
| benzamide, n-((3ar,4r,4ar,5as,6s,6as)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1h)-yl)-4-(trifluoromethyl)-, rel- |
| 4-trifluoromethyl-n-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1h)-yl)-benzamide |
| S3380 |
| n-[(3ar,4r,4ar,5as,6s,6as)-1,3-dioxooctahydro-4,6-ethenocyclopropa[f]isoindol-2(1h)-yl]-4-(trifluoromethyl)benzamide |
| n-(dioxo[?]yl)-4-(trifluoromethyl)benzamide |
| tecovirimat [mi] |
| tecovirimat [who-dd] |
| tecovirimat [inn] |
| tecovirimat [orange book] |
| tecovirimat [usan] |
| n-[(3ar,4r,4ar,5as,6s,6as)-1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa[f]isoindol-2(1h)-yl]-4-(trifluoromethyl)benzamide |
| CS-3464 |
| SCHEMBL404743 |
| HY-14805 |
| SCHEMBL21670085 |
| AKOS030260536 |
| benzamide, n-[(3ar,4r,4ar,5as,6s,6as)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1h)-yl]-4-(trifluoromethyl)-, rel- |
| CHEMBL1257073 |
| DB12020 |
| n-(3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl)-4-(trifluoromethyl)benzamide |
| n-[(1r,2r,6s,7s,8s,10r)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide |
| Q7692792 |
| EX-A4340 |
| arestvyr;iga-246;t-246 |
| st-246st-246 |
| DTXSID101026474 |
| cskdfzimjxrjgh-vwlpuntisa-n |
| j05ax24 |
| tecovirimatum |
| bdbm50577060 |
| n-[(1s,2s,6r,7r,8r,10s)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Envelope phospholipase F13 | Vaccinia virus WR | IC50 | 0.0027 | AID1778687 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID561375 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as percent hematocrit level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized mo | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID279646 | Reduction of Ectromelia virus replication in BALB/c mouse spleen at 100 mg/kg, po once daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543334 | Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID373583 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 10 mg/kg, po treated for 5 days after 1 day of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID1778686 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by neutral red dye based colorimetric analysis | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221ISSN: 1768-3254 | Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity. |
| AID516208 | Cmax in healthy human at 400 mg/day, po administered for 21 days measured at day 1 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID562846 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID563072 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID516217 | AUC in healthy human at 800 mg/day, po administered for 21 days measured at day 6 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID561372 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as blood urea nitrogen level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homoge | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID563074 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID562867 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to contr | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID563063 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID519846 | Toxicity in fasting healthy human assessed as constipation at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID563066 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID543298 | Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID562861 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to contr | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID563087 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against weight loss at 100 mg/kg, po qd for 1 to 3 days measured on day 8 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID540969 | Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516238 | Toxicity in healthy human assessed as incidence of urticaria at 250 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID279654 | Effect on mortality of A/NCr mouse inoculated with ectromelia virus at 100 mg/kg after 24 hrs of viral infection, po once daily for 10 days relative control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID563076 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID543312 | Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561595 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine amino transferase level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homoge | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID563061 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID279597 | Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 4 hrs of viral infection, po once daily for 10 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543331 | Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID519765 | AUClast in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279584 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 24 hrs of viral infection, po once daily for 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID542652 | Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID540984 | Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.015 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279652 | Reduction of Ectromelia virus replication in BALB/c mouse trachea at 100 mg/kg, po once daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID561593 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as temperature change in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID279589 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 24 hrs of viral infection, po once daily for 10 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID1778687 | Inhibition of p37 in Vaccinia virus Copenhagen infected in African green monkey Vero cells assessed as reduction in viral reproduction incubated for 4 days by neutral red dye based colorimetric analysis | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221ISSN: 1768-3254 | Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity. |
| AID563068 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 3 to 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561373 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as creatinine level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogenized mon | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID542155 | Ratio of EC50 for thymidine kinase deficient Cowpox virus harboring TK:GFP lacZ to EC50 for thymidine kinase positive Cowpox virus harboring deltacrmA lacZ | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 ISSN: 1098-6596 | Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. |
| AID279603 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 30 mg/kg after 4 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543313 | Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID540978 | Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID373603 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 3 mg/kg, po treated for 5 days after 6 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID563267 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced death at 100 mg/kg, po qd administered 4 days after postinfection measured on day 6 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561603 | Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as survival of monkey at 300 mg/kg/day, po administered 24 hrs post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscuit measured | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561584 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine phosphatase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID542643 | Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554847 | AUC (0 to 24 hrs) in human at 4.2 mg/kg, po qd for 21 days administered under fed condition measured after 21 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID279655 | Effect on mortality of A/NCr mouse inoculated with ectromelia virus at 100 mg/kg after 48 hrs of viral infection, po once daily for 10 days relative control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID542655 | Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561574 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as blood urea nitrogen level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561589 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as percent hematocrit level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID562868 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to con | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID563082 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in ACAM2000 vaccinated BALB/c mouse assessed as reduction of swab virus titers at 100 mg/kg, po qd measured after 7 days postinfection by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID516228 | Tmax in healthy human at 250 to 800 mg/day, po administered for 21 days measured at day 6 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID543336 | Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516218 | Cmax in healthy human at 250 mg/day, po administered for 21 days measured at day 21 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID279577 | Antiviral activity against Vaccinia virus Copenhagen infected HFF cells | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID561570 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as albumin level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscui | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID279666 | Reduction of Vaccinia virus WR replication in BALB/c mouse lung at 50 mg/kg after 24 hrs of viral infection, po for 9 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID542149 | Antiviral activity against thymidine kinase deficient Cowpox virus harboring TK:GFP lacZ infected in HFF after 48 hrs by beta-galactosidase assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 ISSN: 1098-6596 | Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. |
| AID563081 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in ACAM2000 vaccinated BALB/c mouse assessed as reduction of swab virus titers at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID516255 | Toxicity in healthy human assessed as incidence of somnolence at 800 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID516231 | Toxicity in healthy human assessed as incidence of abnormal eye sensation at 250 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID543291 | Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID563071 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID516234 | Toxicity in healthy human assessed as incidence of nausea at 250 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID373595 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 1 mg/kg, po treated for 5 days after 3 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID554845 | AUC (0 to 24 hrs) in human at 4.2 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID543322 | Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID563096 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in blood at 100 mg/kg, po qd for 1 day by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID279626 | Effect on mortality of A/NCr mouse inoculated with 41 PFU ectromelia virus at 100 mg/kg after 24 hrs of viral infection, po twice daily for 14 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID542641 | Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561590 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as platelet count in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey bisc | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID562865 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to contr | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561587 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as creatinine level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey bis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561597 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as aspartate amino transferase level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homo | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID373585 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 1 mg/kg, po treated for 5 days after 1 day of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID554827 | Cmax in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po qd for 14 days administered under fed condition measured after 7 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID541001 | Antiviral activity against Cowpox virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561571 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine amino transferase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogen | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID563070 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID279608 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 10 mg/kg after 24 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID516212 | Cmax in healthy human at 250 mg/day, po administered for 21 days measured at day 6 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID279644 | Reduction of Ectromelia virus replication in BALB/c mouse spleen at 100 mg/kg, po once daily after 4 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID563086 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced death at 100 mg/kg, po qd for 1 to 3 days | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID562847 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID373608 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 3 mg/kg, po treated for 5 days after 6 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID562863 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to cont | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID554832 | AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 20 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID543307 | Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID432215 | Antiviral activity against Vaccinia virus | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 ISSN: 1768-3254 | Antiviral evaluation of N-amino-1,2,3-triazoles against Cantagalo virus replication in cell culture. |
| AID279600 | Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 24 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID561600 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as total protein level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID540995 | Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.005 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID562844 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in lungs at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID542150 | Antiviral activity against thymidine kinase positive Cowpox virus harboring deltacrmA lacZ infected in HFF after 48 hrs by beta-galactosidase assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 ISSN: 1098-6596 | Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. |
| AID279632 | Reduction of Ectromelia virus replication in BALB/c mouse liver at 100 mg/kg, po once daily after 14 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID542636 | Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID519776 | Median half life in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID554833 | AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID1778690 | Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for inhibition of p37 in Cowpox virus Grishak infected in African green monkey Vero cells | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221ISSN: 1768-3254 | Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity. |
| AID542645 | Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID373589 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 3 mg/kg, po treated for 5 days after 1 day of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID562841 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID543305 | Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279592 | Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 4 hrs of viral infection, po once daily for 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID563073 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID562837 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID516211 | AUC in healthy human at 800 mg/day, po administered for 21 days measured at day 1 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID279664 | Reduction of Cowpox virus BR replication in BALB/c mouse spleen at 50 mg/kg after 24 hrs of viral infection, po for 9 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID540996 | Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.005 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID562859 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 13 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID543314 | Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516206 | Cmax in healthy human at 250 mg/day, po administered for 21 days measured at day 1 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID519770 | AUC(0 to infinity) in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID561378 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as white blood cell count in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monk | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561376 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as platelet count in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscu | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID543311 | Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279588 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 4 hrs of viral infection, po once daily for 10 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID563079 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 in african green monkey BSC-40 cells infected with 7 day postinfection nasal fluid from 100 mg/kg, po qd compound treated BALB/c mouse infected through percutaneous route assessed as reduction of v | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID540983 | Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.015 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID542649 | Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279595 | Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 4 hrs of viral infection, po once daily for 7 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID563266 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced death at 100 mg/kg, po qd administered 3 days after postinfection measured on day 6 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID563097 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in liver at 100 mg/kg, po qd for 1 day by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID542644 | Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554838 | Cmax in human at 4.2 mg/kg, po qd for 21 days administered under fed condition measured after 21 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID562858 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 13 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID432228 | Antiviral activity against Cowpox virus | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 ISSN: 1768-3254 | Antiviral evaluation of N-amino-1,2,3-triazoles against Cantagalo virus replication in cell culture. |
| AID516227 | Tmax in healthy human at 250 to 800 mg/day, po administered for 21 days measured at day 1 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID516223 | Half life in healthy human at 250 mg/day, po administered for 21 days measured at day 21 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID543300 | Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279642 | Reduction of Ectromelia virus replication in BALB/c mouse lung at 100 mg/kg, po once daily after 6 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID279671 | Reduction of Ectromelia virus replication in BALB/c mouse nasal wash at 100 mg/kg, po once daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID516253 | Toxicity in healthy human assessed as incidence of fatigue at 800 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID562869 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to cont | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID563077 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID279663 | Reduction of Cowpox virus BR replication in BALB/c mouse liver at 50 mg/kg after 24 hrs of viral infection, po for 9 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID373735 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 1 mg/kg, po treated for 5 days after 6 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID279639 | Reduction of Ectromelia virus replication in BALB/c mouse liver at 100 mg/kg, po once daily after 6 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID373738 | Antiviral activity against Cowpox virus Brighton in HFF cells assessed as inhibition of viral replication after 7 days | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID279581 | Antiviral activity against Cowpox virus Brighton infected HFF cells | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID279604 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 10 mg/kg after 4 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID540977 | Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID373579 | Cytotoxicity against HFF cells after 7 days by neutral red assay | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID516250 | Toxicity in healthy human assessed as incidence of dry mouth at 800 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID373741 | Antiviral activity against Camelpox virus in HFF cells assessed as inhibition of viral replication after 7 days | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID543338 | Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561581 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as temperature change in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey b | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID562849 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID516252 | Toxicity in healthy human assessed as incidence of nausea at 800 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID373597 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 10 mg/kg, po treated for 5 days after 3 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID519755 | Terminal half life in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID561368 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as albumin level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID519777 | Median half life in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID554822 | Cmax in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID563088 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against weight loss at 100 mg/kg, po qd for 5 to 14 days measured on day 8 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID563095 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd for 3 days by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID542654 | Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279580 | Selectivity index, ratio of CC50 for HFF cells to EC50 for Vaccinia virus WR infected HFF cells | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID519836 | Plasma clearance in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID542648 | Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561578 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as platelet count in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscu | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID373576 | Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID562640 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID562836 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID516219 | AUC in healthy human at 250 mg/day, po administered for 21 days measured at day 21 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID540976 | Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.05 to 5 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516216 | Cmax in healthy human at 800 mg/day, po administered for 21 days measured at day 6 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID554841 | Cmax in human at 6.7 mg/kg, po qd for 21 days administered under fed condition measured after 21 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID519838 | Apparent Cmax in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID519844 | Toxicity in fasting healthy human assessed as adverse events at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID543308 | Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554852 | AUC (0 to 24 hrs) in human at 13.3 mg/kg, po qd for 6 days administered under fed condition measured after 6 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID540991 | Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516229 | Tmax in healthy human at 250 to 800 mg/day, po administered for 21 days measured at day 21 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID543286 | Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID519760 | Cmax in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID373607 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 10 mg/kg, po treated for 5 days after 6 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID561377 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as mean corpuscular hemoglobin concentration in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrat | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID516236 | Toxicity in healthy human assessed as incidence of headache at 250 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID543288 | Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561358 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as decrease in blood viral load at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey b | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID279599 | Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 4 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543339 | Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID519752 | Terminal half life in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID543330 | Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279669 | Reduction of Vaccinia virus WR replication in BALB/c mouse kidney at 50 mg/kg after 24 hrs of viral infection, po for 9 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID563083 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in ACAM2000 vaccinated BALB/c mouse assessed as reduction of swab virus titers at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysi | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID543324 | Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID543299 | Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID519839 | Plasma clearance in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID563090 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against hypothermia at 100 mg/kg, po qd for 1 to 3 days measured on day 6 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561577 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as percent hematocrit level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized mo | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID563092 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in spleen at 100 mg/kg, po qd for 1 day by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561379 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as temperature change in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey b | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561599 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as creatinine level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey bi | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID543294 | Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516207 | AUC in healthy human at 250 mg/day, po administered for 21 days measured at day 1 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID519843 | Toxicity in fasting healthy human assessed as headache at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID516254 | Toxicity in healthy human assessed as incidence of headache at 800 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID561596 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine phosphatase level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID543319 | Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279615 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 30 mg/kg after 72 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID516251 | Toxicity in healthy human assessed as incidence of flatulence at 800 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID543560 | Antiviral activity against J2R gene deficient Vaccinia virus harboring VVTK::luc infected in HFF assessed as reduction of plaque formation after 3 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 ISSN: 1098-6596 | Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. |
| AID540993 | Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID541002 | Antiviral activity against Camelpox virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID542653 | Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561576 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as total protein level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID516244 | Toxicity in healthy human assessed as incidence of fatigue at 400 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID543318 | Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID542634 | Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279637 | Reduction of Ectromelia virus replication in BALB/c mouse nasal wash at 100 mg/kg, po once daily after 14 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID516242 | Toxicity in healthy human assessed as incidence of flatulence at 400 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID540974 | Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.05 to 5 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID562854 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 7 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID540990 | Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561582 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as albumin level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscui | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID540987 | Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.015 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516225 | AUC in healthy human at 800 mg/day, po administered for 21 days measured at day 21 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID279628 | Effect on mortality of A/NCr mouse inoculated with 4100 PFU ectromelia virus at 100 mg/kg after 24 hrs of viral infection, po twice daily for 14 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543320 | Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID542646 | Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID563093 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in spleen at 100 mg/kg, po qd for 3 days by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561598 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as blood urea nitrogen level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID373602 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 10 mg/kg, po treated for 5 days after 6 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID373604 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 1 mg/kg, po treated for 5 days after 6 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID554849 | AUC (0 to 24 hrs) in human at 6.7 mg/kg, po qd for 6 days administered under fed condition measured after 6 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID562856 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 7 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID563064 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID542637 | Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561586 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as blood urea nitrogen level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561606 | Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as log decrease in viral load at 300 mg/kg/day, po administered 72 hrs post infection measured after 14 days | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID554835 | AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po qd for 14 days administered under fed condition measured after 14 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID543332 | Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554825 | Cmax in monkeypox virus infected cynomolgus monkey at 20 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID562843 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in lungs at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID543290 | Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516245 | Toxicity in healthy human assessed as incidence of headache at 400 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID554823 | Cmax in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po qd for 14 days administered under fed condition measured after 7 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID516239 | Toxicity in healthy human assessed as incidence of treatment-emergent adverse events at 400 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID279616 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 10 mg/kg after 72 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID562832 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID373580 | Selectivity index, ratio CC50 for HFF cells to EC50 for Vaccinia virus Copenhagen | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID373582 | Selectivity index, ratio CC50 for HFF cells to EC50 for Cowpox virus Brighton | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID562838 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID279606 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 100 mg/kg after 24 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543296 | Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID540979 | Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561778 | Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as inhibition of virus induced skin lesions at 300 mg/kg/day, po administered 72 hrs post infection measured after 14 days | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID540971 | Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279647 | Reduction of Ectromelia virus replication in BALB/c mouse esophagus at 100 mg/kg, po once daily after 4 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID516220 | Half life in healthy human at 400 mg/day, po administered for 21 days measured at day 21 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID542635 | Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554826 | Cmax in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID563069 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561575 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as creatinine level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey bis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID562830 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID554842 | Cmax in human at 13.3 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID562833 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561588 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as total protein level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID563091 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against hypothermia at 100 mg/kg, po qd for 5 to 14 days | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID373737 | Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as inhibition of viral replication after 7 days | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID543309 | Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID540998 | Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.005 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279596 | Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 24 hrs of viral infection, po once daily for 7 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID562855 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 7 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID562864 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to contr | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID563062 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID554844 | Cmax in human at 13.3 mg/kg, po qd for 21 days administered under fed condition measured after 21 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID519759 | Tmax in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279635 | Reduction of Ectromelia virus replication in BALB/c mouse esophagus at 100 mg/kg, po once daily after 14 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID519778 | Median half life in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID519835 | Plasma clearance in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279625 | Effect on mortality of A/NCr mouse inoculated with 4.1 PFU ectromelia virus at 100 mg/kg after 4 hrs of viral infection, po twice daily for 14 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID561371 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as aspartate amino transferase level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrate | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID373577 | Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID1778689 | Inhibition of p37 in Cowpox virus Grishak infected in African green monkey Vero cells assessed as reduction in viral reproduction incubated for 4 days by neutral red dye based colorimetric analysis | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221ISSN: 1768-3254 | Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity. |
| AID543297 | Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554831 | AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po qd for 14 days administered under fed condition measured after 14 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID563065 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID373590 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 1 mg/kg, po treated for 5 days after 1 day of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID562862 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to contro | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID543326 | Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID542631 | Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561362 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as inhibition of virus-mediated lesion formation at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated hom | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561360 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as log decrease in blood viral load at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monk | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561601 | Immunostimulatory activity in cynomolgus monkey infected with 1X10'8 PFU Variola virus Harper assessed as level of IgM at 300 mg/kg/day, po followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscuit measured on day 7 by ELISA | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID279579 | Antiviral activity against Vaccinia virus WR infected HFF cells | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543333 | Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279640 | Reduction of Ectromelia virus replication in BALB/c mouse liver at 100 mg/kg, po once daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID279582 | Selectivity index, ratio of CC50 for HFF cells to EC50 for Cowpox virus Brighton infected HFF cells | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID519774 | Apparent oral clearance in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID562839 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID540972 | Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.05 to 5 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID543559 | Antiviral activity against ST-246-resistant Vaccinia virus VV911 harboring DNA polymerase E13L mutant infected in HFF assessed as reduction of plaque formation after 3 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 ISSN: 1098-6596 | Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. |
| AID540973 | Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.05 to 5 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID542632 | Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561583 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine amino transferase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogen | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID543558 | Antiviral activity against cidofovir-resistant Vaccinia virus 15A harboring DNA polymerase E9L mutant infected in HFF assessed as reduction of plaque formation after 3 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 ISSN: 1098-6596 | Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. |
| AID279612 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 10 mg/kg after 48 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID554834 | AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po qd for 14 days administered under fed condition measured after 7 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID562831 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID540980 | Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID543310 | Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID540985 | Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.015 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID540970 | Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516222 | AUC in healthy human at 400 mg/day, po administered for 21 days measured at day 21 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID543292 | Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID1778692 | Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for inhibition of p37 in Ectromelia virus K1 infected in African green monkey Vero cells | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221ISSN: 1768-3254 | Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity. |
| AID561367 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as temperature change in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID519848 | Toxicity in healthy human assessed as headache at 1000 mg, po administered as single dose measured after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID563085 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced death at 100 mg/kg, po qd for 5 to 14 days | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID554846 | AUC (0 to 24 hrs) in human at 4.2 mg/kg, po qd for 6 days administered under fed condition measured after 6 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID563094 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd for 1 day by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID279602 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 100 mg/kg after 4 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID516221 | Cmax in healthy human at 400 mg/day, po administered for 21 days measured at day 21 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID516246 | Toxicity in healthy human assessed as incidence of somnolence at 400 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID561355 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as survival of animal at 300 mg/kg/day, po administered immediately post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscu | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID543325 | Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID543302 | Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554836 | Cmax in human at 4.2 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID561356 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as survival of animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscuit mea | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561591 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as mean corpuscular hemoglobin concentration in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydra | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID519775 | Apparent oral clearance in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID540997 | Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.005 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID519766 | AUClast in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279641 | Reduction of Ectromelia virus replication in BALB/c mouse lung at 100 mg/kg, po once daily after 4 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID519756 | Tmax in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279598 | Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 24 hrs of viral infection, po once daily for 10 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543329 | Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID510357 | Cytotoxicity against human CEMx174 5.25M7 cells after 4 days by XTT assay | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 ISSN: 1768-3254 | Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents. |
| AID279660 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 50 mg/kg after 24 hrs of viral infection, po for 9 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID279578 | Selectivity index, ratio of CC50 for HFF cells to EC50 for Vaccinia virus Copenhagen infected HFF cells | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID279668 | Reduction of Vaccinia virus WR replication in BALB/c mouse spleen at 50 mg/kg after 24 hrs of viral infection, po for 9 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID516247 | Toxicity in healthy human assessed as incidence of urticaria at 400 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID563078 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID562835 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID543301 | Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554828 | Cmax in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po qd for 14 days administered under fed condition measured after 14 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID519771 | AUC(0 to infinity) in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID540989 | Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID519772 | Apparent oral clearance in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279649 | Reduction of Ectromelia virus replication in BALB/c mouse esophagus at 100 mg/kg, po once daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID563067 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561364 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as platelet count in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monke | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID373742 | Antiviral activity against Variola virus in HFF cells assessed as inhibition of viral replication after 7 days | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID561592 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as white blood cell count in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized mon | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID516237 | Toxicity in healthy human assessed as incidence of somnolence at 250 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID562857 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 13 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID519757 | Tmax in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279656 | Effect on mortality of A/NCr mouse inoculated with ectromelia virus at 100 mg/kg after 72 hrs of viral infection, po once daily for 10 days relative control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID279583 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 4 hrs of viral infection, po once daily for 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID279670 | Reduction of Ectromelia virus replication in BALB/c mouse nasal wash at 100 mg/kg, po once daily after 6 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID561573 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as aspartate amino transferase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homog | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID279591 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 24 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543315 | Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID563098 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in brain at 100 mg/kg, po qd for 1 day by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID519842 | Toxicity in fasting healthy human assessed as back pain at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279638 | Reduction of Ectromelia virus replication in BALB/c mouse liver at 100 mg/kg, po once daily after 4 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID540988 | Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561607 | Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as inhibition of virus induced skin lesions at 300 mg/kg/day, po administered 24 hrs post infection measured after 14 days | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID279590 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 4 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID519758 | Tmax in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID519845 | Toxicity in fasting healthy human assessed as neutropenia at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID542166 | Antiviral activity against Vaccinia virus WR infected in HFF assessed as reduction of plaque formation after 3 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 ISSN: 1098-6596 | Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. |
| AID373598 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 3 mg/kg, po treated for 5 days after 3 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID279648 | Reduction of Ectromelia virus replication in BALB/c mouse esophagus at 100 mg/kg, po once daily after 6 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID554824 | Cmax in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po qd for 14 days administered under fed condition measured after 14 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID543306 | Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279627 | Effect on mortality of A/NCr mouse inoculated with 410 PFU ectromelia virus at 100 mg/kg after 24 hrs of viral infection, po twice daily for 14 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID563080 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 in african green monkey BSC-40 cells infected with 7 day postinfection BAL fluid from 100 mg/kg, po qd compound treated BALB/c mouse infected through percutaneous route assessed as reduction of vir | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID543293 | Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279645 | Reduction of Ectromelia virus replication in BALB/c mouse spleen at 100 mg/kg, po once daily after 6 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID561580 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as white blood cell count in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monk | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID562850 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID562853 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 7 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID373584 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 3 mg/kg, po treated for 5 days after 1 day of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID561594 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as albumin level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscu | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID519841 | Toxicity in fasting healthy human assessed as feeling abnormal at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID373739 | Antiviral activity against Ectromelia virus Moscow in HFF cells assessed as inhibition of viral replication after 7 days | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID541003 | Antiviral activity against Ectromelia virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID563100 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in liver at 100 mg/kg, po qd for 3 to 14 days by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561361 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as inhibition of virus-mediated lesion formation at 300 mg/kg/day, po administered immediately post infection followed by 5 ml/kg of 30% suspension of hydrat | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID279651 | Reduction of Ectromelia virus replication in BALB/c mouse trachea at 100 mg/kg, po once daily after 6 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID561579 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as mean corpuscular hemoglobin concentration in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrat | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID562848 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561602 | Immunostimulatory activity in cynomolgus monkey infected with 1X10'8 PFU Variola virus Harper assessed as level of IgG at 300 mg/kg/day, po followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscuit measured on day 7 by ELISA | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561357 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as decrease in blood viral load at 300 mg/kg/day, po administered immediately post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized mo | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID516241 | Toxicity in healthy human assessed as incidence of dry mouth at 400 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID519762 | Cmax in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID563060 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to cont | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID540992 | Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554851 | AUC (0 to 24 hrs) in human at 13.3 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID373599 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 1 mg/kg, po treated for 5 days after 3 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID279614 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 100 mg/kg after 72 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543328 | Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID543287 | Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID540994 | Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.005 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561363 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as percent hematocrit level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogen | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID542642 | Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID1778688 | Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for inhibition of p37 in Vaccinia virus Copenhagen infected in African green monkey Vero cells | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221ISSN: 1768-3254 | Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity. |
| AID516215 | AUC in healthy human at 400 mg/day, po administered for 21 days measured at day 6 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID543316 | Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279650 | Reduction of Ectromelia virus replication in BALB/c mouse trachea at 100 mg/kg, po once daily after 4 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID561365 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as mean corpuscular hemoglobin concentration in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID519754 | Terminal half life in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID373578 | Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID279661 | Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 50 mg/kg after 24 hrs of viral infection, po for 9 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID561370 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine phosphatase level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homoge | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID542640 | Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516243 | Toxicity in healthy human assessed as incidence of nausea at 400 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID542639 | Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516224 | Cmax in healthy human at 800 mg/day, po administered for 21 days measured at day 21 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID279587 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 24 hrs of viral infection, po once daily for 7 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID516226 | Half life in healthy human at 800 mg/day, po administered for 21 days measured at day 21 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID540999 | Antiviral activity against Variola virus infected in african green monkey vero cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID543289 | Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID540975 | Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.05 to 5 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID519840 | Toxicity in fasting healthy human assessed as adverse events at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID562851 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID373594 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 3 mg/kg, po treated for 5 days after 3 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID554853 | AUC (0 to 24 hrs) in human at 13.3 mg/kg, po qd for 21 days administered under fed condition measured after 21 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID519768 | AUC(0 to infinity) in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID543337 | Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516256 | Toxicity in healthy human assessed as incidence of urticaria at 800 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID510356 | Antiviral activity against R5 tropic HIV1 BaL infected in human CEMx174 5.25M7 cells after 3 days by luciferase assay | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 ISSN: 1768-3254 | Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents. |
| AID279611 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 30 mg/kg after 48 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID279586 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 4 hrs of viral infection, po once daily for 7 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID562866 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to cont | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID562852 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561374 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as total protein level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogenized | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID373740 | Antiviral activity against Monkeypox virus in HFF cells assessed as inhibition of viral replication after 7 days | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID279643 | Reduction of Ectromelia virus replication in BALB/c mouse lung at 100 mg/kg, po once daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID542650 | Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279634 | Reduction of Ectromelia virus replication in BALB/c mouse spleen at 100 mg/kg, po once daily after 14 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID516210 | Cmax in healthy human at 800 mg/day, po administered for 21 days measured at day 1 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID554850 | AUC (0 to 24 hrs) in human at 6.7 mg/kg, po qd for 21 days administered under fed condition measured after 21 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID519837 | Plasma clearance in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID554840 | Cmax in human at 6.7 mg/kg, po qd for 6 days administered under fed condition measured after 6 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID516213 | AUC in healthy human at 250 mg/day, po administered for 21 days measured at day 6 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID563075 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID519769 | AUC(0 to infinity) in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279653 | Effect on mortality of A/NCr mouse inoculated with ectromelia virus at 100 mg/kg after 0 hrs of viral infection, po once daily for 10 days relative control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID554839 | Cmax in human at 6.7 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID562834 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID540986 | Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.015 uM | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID542638 | Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554837 | Cmax in human at 4.2 mg/kg, po qd for 6 days administered under fed condition measured after 6 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID519847 | Toxicity in healthy human assessed as adverse events at 1000 mg, po administered as single dose measured after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID561585 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as aspartate amino transferase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homog | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID279607 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 30 mg/kg after 24 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID519767 | AUClast in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID373581 | Selectivity index, ratio CC50 for HFF cells to EC50 for Vaccinia virus WR | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID542647 | Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID561359 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as log decrease in blood viral load at 300 mg/kg/day, po administered immediately post infection followed by 5 ml/kg of 30% suspension of hydrated homogenize | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID373593 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 10 mg/kg, po treated for 5 days after 3 days of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID516249 | Toxicity in healthy human assessed as incidence of abnormal eye sensation at 800 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID561605 | Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as log decrease in viral load at 300 mg/kg/day, po administered 24 hrs post infection followed by 5 ml/kg of monkey biscuit measured after 14 days | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID279662 | Reduction of Cowpox virus BR replication in BALB/c mouse lung at 50 mg/kg after 24 hrs of viral infection, po for 9 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID516209 | AUC in healthy human at 400 mg/day, po administered for 21 days measured at day 1 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID541000 | Antiviral activity against Monkeypox virus infected in african green monkey vero cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID562840 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID279610 | Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 100 mg/kg after 48 hrs of viral infection, po once daily for 14 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID542630 | Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID519764 | AUClast in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279665 | Reduction of Cowpox virus BR replication in BALB/c mouse kidney at 50 mg/kg after 24 hrs of viral infection, po for 9 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID543327 | Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516240 | Toxicity in healthy human assessed as incidence of abnormal eye sensation at 400 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID563084 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in ACAM2000 vaccinated BALB/c mouse assessed as reduction of swab virus titers at 100 mg/kg, po qd measured after 21 days postinfection by RT-PCR analysi | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID542633 | Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID519753 | Terminal half life in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID279576 | Cytotoxicity against HFF cells | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID519773 | Apparent oral clearance in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID543321 | Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID543304 | Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516232 | Toxicity in healthy human assessed as incidence of dry mouth at 250 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID561369 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine amino transferase level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID554829 | AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID554843 | Cmax in human at 13.3 mg/kg, po qd qd for 6 days administered under fed condition measured after 6 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID562860 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 13 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID543323 | Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID543303 | Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID563089 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against hypothermia at 100 mg/kg, po qd for 1 to 3 days measured on day 2 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID563099 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in blood at 100 mg/kg, po qd for 3 to 14 days by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID542154 | Antiviral activity against Vaccinia virus WR infected in HFF assessed as inhibition of DNA synthesis after 24 hrs by PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 ISSN: 1098-6596 | Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. |
| AID543317 | Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516230 | Toxicity in healthy human assessed as incidence of treatment-emergent adverse events at 250 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID540982 | Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID516235 | Toxicity in healthy human assessed as incidence of fatigue at 250 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID519761 | Cmax in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID543295 | Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID554830 | AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po qd for 14 days administered under fed condition measured after 7 days | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID562845 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID516233 | Toxicity in healthy human assessed as incidence of flatulence at 250 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID562842 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID1778691 | Inhibition of p37 in Ectromelia virus K1 infected in African green monkey Vero cells assessed as reduction in viral reproduction incubated for 4 days by neutral red dye based colorimetric analysis | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221ISSN: 1768-3254 | Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity. |
| AID543335 | Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID562641 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561604 | Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as survival of monkey at 300 mg/kg/day, po administered 72 hrs post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscuit measured | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID563265 | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in brain at 100 mg/kg, po qd for 3 to 14 days by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 ISSN: 1098-6596 | ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. |
| AID561366 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as white blood cell count in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogeniz | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID561572 | Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine phosphatase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 ISSN: 1098-6596 | Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. |
| AID516248 | Toxicity in healthy human assessed as incidence of treatment-emergent adverse events at 800 mg/day, po administered for 21 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID279667 | Reduction of Vaccinia virus WR replication in BALB/c mouse liver at 50 mg/kg after 24 hrs of viral infection, po for 9 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID519763 | Cmax in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 ISSN: 1098-6596 | Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. |
| AID373588 | Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 10 mg/kg, po treated for 5 days after 1 day of viral inoculation | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 ISSN: 0066-4804 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. |
| AID516214 | Cmax in healthy human at 400 mg/day, po administered for 21 days measured at day 6 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 ISSN: 1098-6596 | Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. |
| AID279636 | Reduction of Ectromelia virus replication in BALB/c mouse trachea at 100 mg/kg, po once daily after 14 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID540981 | Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID542651 | Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 ISSN: 1098-6596 | In vitro efficacy of ST246 against smallpox and monkeypox. |
| AID279633 | Reduction of Ectromelia virus replication in BALB/c mouse lung at 100 mg/kg, po once daily after 14 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| AID554848 | AUC (0 to 24 hrs) in human at 6.7 mg/kg, po administered as single dose under fed condition measured after 1 day | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 ISSN: 1098-6596 | ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. |
| AID279593 | Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 24 hrs of viral infection, po once daily for 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 ISSN: 0066-4804 | Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (25.58) | 29.6817 |
| 2010's | 42 (48.84) | 24.3611 |
| 2020's | 22 (25.58) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 6 (6.82%) | 5.53% |
| Reviews | 9 (10.23%) | 6.00% |
| Case Studies | 6 (6.82%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 67 (76.14%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| nevirapine | cyclopropanes; dipyridodiazepine | antiviral drug; HIV-1 reverse transcriptase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| idoxuridine | organoiodine compound; pyrimidine 2'-deoxyribonucleoside | antiviral drug; DNA synthesis inhibitor | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| cidofovir anhydrous | phosphonic acids; pyrimidone | anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent | 2007 | 2009 | 16.0 | low | 0 | 0 | 0 | 4 | 0 | 0 | |
| 4'-thiothymidine | 2009 | 2009 | 15.0 | high | 0 | 0 | 0 | 1 | 0 | 0 | |||
| tak 779 | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |||
| cmx 001 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |||
| indinavir sulfate | dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide | HIV protease inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| 2'-deoxy-4'-thiocytidine | 2009 | 2009 | 15.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 Novel Coronavirus Disease | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 3 | |
| Action Tremor | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Acute Myelogenous Leukemia | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Alastrim | 0 | 2008 | 2022 | 7.4 | high | 0 | 0 | 0 | 4 | 18 | 5 | |
| Animal Diseases | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Body Weight | 0 | 2013 | 2015 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 | |
| Bovine Diseases | 0 | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Communicable Diseases, Emerging | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Cow Pox | 0 | 2009 | 2021 | 9.0 | low | 0 | 0 | 0 | 1 | 0 | 1 | |
| Dermatitis, Atopic | 0 | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Disease Models, Animal | 0 | 2007 | 2020 | 10.1 | medium | 2 | 0 | 0 | 4 | 9 | 0 | |
| Ectromelia, Infectious | 0 | 2005 | 2012 | 14.7 | low | 0 | 0 | 0 | 1 | 2 | 0 | |
| Eczema Herpeticum | 0 | 2007 | 2008 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 | |
| Eczema, Atopic | 0 | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Eye Infections, Viral | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| Infections, Poxviridae | 0 | 2005 | 2021 | 12.5 | medium | 2 | 0 | 0 | 8 | 6 | 1 | |
| Infections, Respiratory | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Leukemia, Myeloid, Acute | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Neutropenia | 0 | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Proctitis | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| Respiratory Tract Infections | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Smallpox | 1 | 2008 | 2022 | 7.4 | high | 0 | 0 | 0 | 4 | 18 | 5 | |
| Tremor | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Uveitis | 0 | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| Vaccinia | 0 | 2005 | 2021 | 12.8 | low | 0 | 0 | 0 | 5 | 3 | 1 | |
| Viral Zoonoses | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| Zoonoses | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrobial agents and chemotherapy, , Volume: 56, Issue:9 | 2012 |
| Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys. PloS one, , Volume: 6, Issue:8 | 2011 |
| Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrobial agents and chemotherapy, , Volume: 54, Issue:6 | 2010 |
| Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrobial agents and chemotherapy, , Volume: 52, Issue:5 | 2008 |
| Article | Year |
|---|---|
| Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrobial agents and chemotherapy, , Volume: 56, Issue:9 | 2012 |
| Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrobial agents and chemotherapy, , Volume: 54, Issue:6 | 2010 |
| Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrobial agents and chemotherapy, , Volume: 53, Issue:6 | 2009 |
| ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrobial agents and chemotherapy, , Volume: 53, Issue:5 | 2009 |
| Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrobial agents and chemotherapy, , Volume: 51, Issue:11 | 2007 |
| Article | Year |
|---|---|
| Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Antimicrobial agents and chemotherapy, , Volume: 59, Issue:7 | 2015 |
| Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine, , Feb-13, Volume: 26, Issue:7 | 2008 |